-
The EU approves Qinlock's first fourth-line GIST drug has been launched in China
Time of Update: 2022-01-04
Zai Lab partner Deciphera Pharmaceuticals recently announced that the European Commission (EC) has approved the targeted anti-cancer drug Qinlock (Chinese trade name: Qingle®, generic name: ripretinib, Ripetinib) for fourth-line treatment of gastrointestinal tract GIST (GIST), the drug is specifically applicable to: Adult patients with advanced GIST who have previously received 3 or more kinase inhibitor treatments (including imatinib) .
-
In the next 4 years, it is expected to submit 14 potential blockbuster new drug listing applications. Johnson & Johnson presents its R&D blueprint
Time of Update: 2022-01-04
▲Introduction to Nipocalimab (picture source: Johnson & Johnson's official website)In a phase 2 clinical trial for the treatment of myasthenia gravis (a rare disease in which autoantibodies block nerve synaptic signaling), nipocalimab was treated for two weeks and a significant response was observed in patients .
-
IPO lined up for nearly 5 months, this pharmaceutical company pressed the "stop button"
Time of Update: 2022-01-03
In recent news, another biopharmaceutical company "Zheji" Sci-tech Innovation Board terminates its IPO: The Shanghai Stock Exchange has decided to terminate the initial public offering of Hangzhou Suoyuan Bio-Pharmaceutical Co.
-
Takeda's CMV drug Livtencity receives FDA approval and sales are expected to reach US$800 million
Time of Update: 2022-01-03
CompilationFan DongdongRecently, the US FDA has approved Takeda Livtencity (maribavir) to treat patients with cytomegalovirus (CMV) infection after transplantation in adults or children 12 years of age or older .
-
The API industry has sounded the "innovation-driven" clarion call; upstream will see business opportunities
Time of Update: 2022-01-03
Under the new situation where the quality of API products is improving and green and low-carbon become the main theme of development, the clarion call for the innovation and development of the API industry has been sounded, and it is expected that the upstream equipment industry will also usher in business opportunities .
-
Yasheng Pharmaceutical appointed Chen Yiqing as Chief Financial Officer
Time of Update: 2022-01-03
Chen Yiqing, 37 years old, served as the Deputy Chief Financial Officer and General Manager of the Investor Relations and Capital Development Department of Shanghai Fosun Pharmaceutical (Group) Co.
-
Official implementation on December 1st: at least two licensed pharmacists in such pharmacies
Time of Update: 2022-01-03
In July, the relevant documents issued by Jiangsu Province mentioned that dual-channel pharmacies need to "equipped with four or more professional and responsible pharmacy professionals", including two or more licensed pharmacists and one or more full-time delivery personnel.
-
Competition between domestic and foreign pharmaceutical machinery companies has intensified, and import substitution may become an inevitable trend
Time of Update: 2022-01-03
It is understood that for a long time before, China's domestic pharmaceutical equipment market was mainly concentrated in the low-end field, with low-level repetitive production and low-price competition as the main focus, while the high-end market basically relied on imports .
-
Innovative traditional Chinese medicines ushered in the harvest period, and 4 products were approved for marketing in November
Time of Update: 2022-01-03
In addition to the approval of the above three innovative Chinese medicines, the National Medical Products Administration also approved the registration application for Yinqiao Qingre Tablets in November, which means that a total of 4 innovative Chinese medicines have been approved for marketing .
-
Inventory of laws and regulations and industry practices for the fresh-cut processing industry chain
Time of Update: 2022-01-03
In the agreement, it must be stated that the company engaged in fresh-cutting needs to abide by national laws and regulations, establish a quality system, and engage in the cutting of medicinal materials in accordance with GMP requirements .
-
Pfizer sues employees who will leave this month for allegedly stealing a large number of trade secrets of the new crown vaccine
Time of Update: 2022-01-03
The indictment stated that in October of this year, the technology detected that Li Chunxiao had transferred 12,000 files from her Pfizer laptop to an online Google Drive account .
-
Merck's new crown specific drug final data is lower than estimated Pfizer decides to increase Paxlovid production capacity
Time of Update: 2022-01-03
CompilationTom LeePfizer CEO Albert Bourla said in an interview with CNBC television in the US on Monday that Pfizer now expects to produce 80 million courses of the COVID drug Paxlovid by the end of 2022 .
-
Prospects for the pharmaceutical equipment industry in 2022: the boom is particularly strong, and the growth rate may slow down
Time of Update: 2022-01-03
Looking back at 2021, affected by the transformation and upgrading of the downstream pharmaceutical industry and the accelerated pace of substitution of domestic pharmaceutical equipment for imports, the entire pharmaceutical equipment industry still has a high degree of prosperity .
-
Another domestic pharmaceutical company will enter the tens of billions of dollars in the large-variety drug market
Time of Update: 2022-01-03
Therefore, the industry expects that if the evaluation can be successfully passed, the sales potential of Yangtze River's 4 generic drugs of apixaban tablets will be very considerable .
-
@140 million diabetics, the price of these drugs is cut by nearly half!
Time of Update: 2022-01-03
Judging from the procurement results, the average price of the selected products in this centralized procurement will be reduced by 48%, which is expected to save 9 billion yuan each year .
-
Kangfang Bio-PD-1/VEGF dual antibody initiates phase 3 clinical treatment of non-small cell lung cancer
Time of Update: 2022-01-03
ArticleMedicine GuanlanAccording to the Chinese drug clinical trial registration and information disclosure platform, Kangfang Bio has initiated a phase 3 clinical study of AK112 or placebo combined with chemotherapy for non-small cell lung cancer (NSCLC) patients who have failed EGFR-TKI treatment .
-
DPP1 inhibitor ill-fated, AstraZeneca brensocatib changes hands and takes a turn for the better
Time of Update: 2022-01-03
In September 2020, Insmed announced that the Phase 2 clinical study WILLOW of brensocatib in the treatment of non-cystic fibrosis bronchiectasis (NCFBE) reached the primary endpoint .
-
The quantity of Chinese medicinal materials is small and the price is high. What impact will it have on Chinese medicine companies?
Time of Update: 2022-01-03
In fact, compared with pharmaceutical companies, the industry believes that the increase in the price of Chinese medicinal materials will have a greater impact on planting companies .
-
Announcement of the results of the national centralized drug procurement (special insulin project)
Time of Update: 2022-01-03
Attachment 1 : Selection result table of national centralized drug procurement (insulin special item) Attachment 2: List of products to be supplied after the selection in the national centralized drug procurement (insulin special item) On the afternoon of November 30th, Shanghai Sunshine Pharmaceutical Purchasing Network issued an announcement stating that in accordance with the "National Drug Centralized Purchasing Document (Insulin Special) (GY-YD2021-3)", the Joint Purchasing Office has carried out special centralized purchasing of insulin.
-
From structure to clinical muscarinic M1 receptor agonist may become a new treatment for AD
Time of Update: 2022-01-03
The researchers detailed a new molecular drug they designed to selectively target specific receptor proteins in the brain, and demonstrated the potential of this method in the development of new drugs to improve the cognitive function of patients with Alzheimer's disease .
